



May 5, 2009

Dear Customer,

Millipore's Global Operations function has been monitoring the threat of an influenza pandemic, such as the current outbreak of Influenza A (H1N1) for over four years. We had implemented a Pandemic Preparedness Program in 2007 as a key component of Business Continuity planning. This program has been updated in response to the H1N1 situation and certain elements are already in effect. A full description of the program can be found on our web site at <http://www.millipore.com/pandemicpreparedness>

We would like to assure you that no Millipore products are produced in Mexico.

As part of our ongoing support to our customers and to vaccine manufacturers in particular, we are actively monitoring customer demand and performing capacity and scenario analyses for our raw materials, finished product and inventories. Further we are working with our suppliers to ensure continuity of supply. We do not anticipate any disruption to supply at this time.

We welcome any specific question you may have with regards to Millipore's Pandemic Preparedness program or product supply. We will update our website with relevant information as it becomes available.

Robert Shaw
Program Director Vaccines and Emerging Biotech
Millipore BioProcess
Robert_shaw@millipore.com
1-800-MILLIPORE, extension 2511
781-533-2511